Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease

Nature, 534(7607), 383-386

DOI 10.1038/nature18303 PMID 27281217

Abstract

Of the 237 women, 92 (38.8%) had experienced both a normal and a toxaemic pregnancy, and 72 (78%) contrasted the sense of well-being associated with a normal pregnancy with the malaise and minor symptoms characteristic of the toxaemic condition. The striking feature of these early minor symptoms of toxaemia was their close resemblance to those of premenstrual syndrome noted in an earlier investigation (Greene and Dalton, 1953), most patients confirming that the minor symptoms during their toxaemic pregnancy were similar, though of increased severity, to those experienced in the premenstruum, irrespective of whether the onset of premenstrual syndrome had preceded or followed the toxaemic pregnancy.

Topics

pronuclear transfer mitochondrial disease prevention, mitochondrial DNA replacement therapy, mitochondrial donation clinical application, three-parent IVF mitochondrial disease, nuclear genome transfer oocytes, mtDNA disease prevention technique, mitochondrial replacement therapy ethics, pronuclear transfer zygote manipulation, inherited mitochondrial disorder prevention, assisted reproduction mitochondrial disease
PMID 27281217 27281217 DOI 10.1038/nature18303 10.1038/nature18303

Cite this article

Hyslop, L. A., Blakeley, P., Craven, L., Richardson, J., Fogarty, N. M. E., Fragouli, E., Lamb, M., Wamaitha, S. E., Prathalingam, N., Zhang, Q., O'Keefe, H., Takeda, Y., Arizzi, L., Alfarawati, S., Tuppen, H. A., Irving, L., Kalleas, D., Choudhary, M., Wells, D., . . . Herbert, M. (2016). Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. *Nature*, *534*(7607), 383-386. https://doi.org/10.1038/nature18303

Related articles